Skip to main content
CG Invites Co., Ltd. logo

CG Invites Co., Ltd. — Investor Relations & Filings

Ticker · 083790 ISIN · KR7083790006 KO Manufacturing
Open in API
Filings indexed 450 across all filing types
Latest filing 2023-03-28 Legal Proceedings Report
Country KR South Korea
Listing KO 083790

About CG Invites Co., Ltd.

https://cginvites.com/en

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized medicine. The company's activities are focused on four main areas: genomics, personalized cancer vaccines, digital therapeutics, and the development of chemical and biological drugs. It utilizes Whole Genome Sequencing to support precision medicine initiatives and develops mRNA-based personalized cancer vaccines. The company also creates software-based medical interventions, known as digital therapeutics. Its drug development pipeline includes therapeutics for oncology and inflammatory diseases, such as Acelex for osteoarthritis, Ivaltinostat for pancreatic cancer, and Camrelizumab for immuno-oncology. The company's research approach is based on structural chemoproteomics and the integration of genomic data to develop targeted treatments.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(소송등의제기)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서(소송 등의 제기)' (Major Report: Filing of Lawsuit, etc.) and is a correction filing ('정정신고'). It details legal proceedings regarding an injunction on voting rights ('의결권행사금지가처분'). Since the document pertains to significant legal matters and litigation involving the company, it falls under the 'Legal Proceedings Report' category.
2023-03-28 Korean
주요사항보고서(소송등의제기)
Legal Proceedings Report Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the filing of a lawsuit (소송 등의 제기), specifically an injunction to prohibit the exercise of voting rights (의결권행사금지가처분). This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2023-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement (RNS) rather than the full, multi-page audited financial report itself. It follows the format of a summary disclosure required by Korean regulatory authorities upon the receipt of an audit report. FY 2022
2023-03-21 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for CrystalGenomics, Inc. for the fiscal year 2022. It contains detailed financial data, business operations, management discussions, and organizational structure, which is the standard format for an annual filing in South Korea (equivalent to a 10-K). FY 2022
2023-03-21 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by CrystalGenomics. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2023-03-14 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Supervisory Service/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the 'Share Issue/Capital Change' category.
2023-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.